Thiotepa

Profil Farmakokinetik

Waktu Paruh (Half-Life) 1.5 to 4.1 hours

Volume Distribusi -

Klirens (Clearance) * 446 +/- 63 mL/min [female patients (45 to 84 years) with advanced stage ovarian cancer receiving 60 mg and 80 mg thiotepa by intravenous infusion on subsequent courses given at 4-week intervals]

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Urinary excretion of 14C-labeled thiotepa and metabolites in a 34-year old patient with metastatic carcinoma of the cecum who received a dose of 0.3 mg/kg intravenously was 63%.

Interaksi Makanan

2 Data

1. Exercise caution with grapefruit products. Grapefruit inhibits the CYP3A4 metabolism of thiotepa, which may increase its serum concentration.
2. Exercise caution with St. John's Wort. This herb induces CYP3A4 metabolism and may reduce serum levels of thiotepa.

Interaksi Obat

1126 Data

Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Thiotepa.
Peginterferon alfa-2a	The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Thiotepa.
Interferon alfa-n1	The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Thiotepa.
Interferon alfa-n3	The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Thiotepa.
Peginterferon alfa-2b	The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Thiotepa.
Interferon gamma-1b	The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Thiotepa.
Interferon alfa-2a	The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Thiotepa.
Gemtuzumab ozogamicin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Thiotepa.
Pegaspargase	The risk or severity of adverse effects can be increased when Pegaspargase is combined with Thiotepa.
Interferon beta-1b	The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Thiotepa.
Interferon alfacon-1	The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Thiotepa.
Rituximab	The risk or severity of adverse effects can be increased when Rituximab is combined with Thiotepa.
Basiliximab	The risk or severity of adverse effects can be increased when Basiliximab is combined with Thiotepa.
Muromonab	The risk or severity of adverse effects can be increased when Muromonab is combined with Thiotepa.
Ibritumomab tiuxetan	The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Thiotepa.
Tositumomab	The risk or severity of adverse effects can be increased when Tositumomab is combined with Thiotepa.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Thiotepa.
Alefacept	The risk or severity of adverse effects can be increased when Alefacept is combined with Thiotepa.
Efalizumab	The risk or severity of adverse effects can be increased when Efalizumab is combined with Thiotepa.
Antithymocyte immunoglobulin (rabbit)	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Thiotepa.
Interferon alfa-2b	The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Thiotepa.
Daclizumab	The risk or severity of adverse effects can be increased when Daclizumab is combined with Thiotepa.
Phenylalanine	The risk or severity of adverse effects can be increased when Phenylalanine is combined with Thiotepa.
Bortezomib	The risk or severity of adverse effects can be increased when Bortezomib is combined with Thiotepa.
Cladribine	Thiotepa may increase the immunosuppressive activities of Cladribine.
Carmustine	The risk or severity of adverse effects can be increased when Carmustine is combined with Thiotepa.
Amsacrine	The risk or severity of adverse effects can be increased when Amsacrine is combined with Thiotepa.
Bleomycin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Thiotepa.
Chlorambucil	The risk or severity of adverse effects can be increased when Chlorambucil is combined with Thiotepa.
Raltitrexed	The risk or severity of adverse effects can be increased when Raltitrexed is combined with Thiotepa.
Mitomycin	The risk or severity of adverse effects can be increased when Mitomycin is combined with Thiotepa.
Vindesine	The risk or severity of adverse effects can be increased when Vindesine is combined with Thiotepa.
Floxuridine	The risk or severity of adverse effects can be increased when Floxuridine is combined with Thiotepa.
Indomethacin	The risk or severity of adverse effects can be increased when Indomethacin is combined with Thiotepa.
Tioguanine	The risk or severity of adverse effects can be increased when Tioguanine is combined with Thiotepa.
Vinorelbine	The risk or severity of adverse effects can be increased when Vinorelbine is combined with Thiotepa.
Dexrazoxane	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Thiotepa.
Streptozocin	The risk or severity of adverse effects can be increased when Streptozocin is combined with Thiotepa.
Trifluridine	The risk or severity of adverse effects can be increased when Trifluridine is combined with Thiotepa.
Gemcitabine	The risk or severity of adverse effects can be increased when Gemcitabine is combined with Thiotepa.
Epirubicin	The risk or severity of adverse effects can be increased when Epirubicin is combined with Thiotepa.
Lenalidomide	The risk or severity of adverse effects can be increased when Lenalidomide is combined with Thiotepa.
Altretamine	The risk or severity of adverse effects can be increased when Altretamine is combined with Thiotepa.
Zidovudine	The risk or severity of adverse effects can be increased when Zidovudine is combined with Thiotepa.
Cisplatin	The risk or severity of adverse effects can be increased when Cisplatin is combined with Thiotepa.
Oxaliplatin	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Thiotepa.
Vincristine	The risk or severity of adverse effects can be increased when Vincristine is combined with Thiotepa.
Fluorouracil	The risk or severity of adverse effects can be increased when Fluorouracil is combined with Thiotepa.
Propylthiouracil	The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Thiotepa.
Pentostatin	The risk or severity of adverse effects can be increased when Pentostatin is combined with Thiotepa.
Methotrexate	The risk or severity of adverse effects can be increased when Methotrexate is combined with Thiotepa.
Linezolid	The risk or severity of adverse effects can be increased when Linezolid is combined with Thiotepa.
Clofarabine	The risk or severity of adverse effects can be increased when Clofarabine is combined with Thiotepa.
Pemetrexed	The risk or severity of adverse effects can be increased when Pemetrexed is combined with Thiotepa.
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Thiotepa.
Irinotecan	The risk or severity of adverse effects can be increased when Irinotecan is combined with Thiotepa.
Sulfasalazine	The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Thiotepa.
Dacarbazine	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Thiotepa.
Temozolomide	The risk or severity of adverse effects can be increased when Temozolomide is combined with Thiotepa.
Penicillamine	The risk or severity of adverse effects can be increased when Penicillamine is combined with Thiotepa.
Mechlorethamine	The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Thiotepa.
Azacitidine	The risk or severity of adverse effects can be increased when Azacitidine is combined with Thiotepa.
Carboplatin	The risk or severity of adverse effects can be increased when Carboplatin is combined with Thiotepa.
Dactinomycin	The risk or severity of adverse effects can be increased when Dactinomycin is combined with Thiotepa.
Cytarabine	The risk or severity of adverse effects can be increased when Cytarabine is combined with Thiotepa.
Azathioprine	The risk or severity of adverse effects can be increased when Azathioprine is combined with Thiotepa.
Hydroxyurea	The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Thiotepa.
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Thiotepa.
Mercaptopurine	The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Thiotepa.
Thalidomide	The metabolism of Thiotepa can be increased when combined with Thalidomide.
Melphalan	The risk or severity of adverse effects can be increased when Melphalan is combined with Thiotepa.
Fludarabine	The risk or severity of adverse effects can be increased when Fludarabine is combined with Thiotepa.
Flucytosine	The risk or severity of adverse effects can be increased when Flucytosine is combined with Thiotepa.
Capecitabine	The risk or severity of adverse effects can be increased when Capecitabine is combined with Thiotepa.
Procarbazine	The risk or severity of adverse effects can be increased when Procarbazine is combined with Thiotepa.
Arsenic trioxide	The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Thiotepa.
Idarubicin	The risk or severity of adverse effects can be increased when Idarubicin is combined with Thiotepa.
Estramustine	The risk or severity of adverse effects can be increased when Estramustine is combined with Thiotepa.
Lomustine	The risk or severity of adverse effects can be increased when Lomustine is combined with Thiotepa.
Eculizumab	The risk or severity of adverse effects can be increased when Eculizumab is combined with Thiotepa.
Decitabine	The risk or severity of adverse effects can be increased when Decitabine is combined with Thiotepa.
Nelarabine	The risk or severity of adverse effects can be increased when Nelarabine is combined with Thiotepa.
Stepronin	The risk or severity of adverse effects can be increased when Stepronin is combined with Thiotepa.
Hydroxychloroquine	The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Thiotepa.
Castanospermine	The risk or severity of adverse effects can be increased when Castanospermine is combined with Thiotepa.
Vorinostat	The risk or severity of adverse effects can be increased when Vorinostat is combined with Thiotepa.
2-Methoxyethanol	The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Thiotepa.
Brequinar	The risk or severity of adverse effects can be increased when Brequinar is combined with Thiotepa.
Pirfenidone	The risk or severity of adverse effects can be increased when Thiotepa is combined with Pirfenidone.
Belinostat	The risk or severity of adverse effects can be increased when Thiotepa is combined with Belinostat.
Trabectedin	The risk or severity of adverse effects can be increased when Thiotepa is combined with Trabectedin.
Interferon alfa	The risk or severity of adverse effects can be increased when Thiotepa is combined with Interferon alfa.
Glatiramer	The risk or severity of adverse effects can be increased when Thiotepa is combined with Glatiramer.
Briakinumab	The risk or severity of adverse effects can be increased when Thiotepa is combined with Briakinumab.
Human interferon omega-1	The risk or severity of adverse effects can be increased when Thiotepa is combined with Human interferon omega-1.
Panobinostat	The risk or severity of adverse effects can be increased when Thiotepa is combined with Panobinostat.
Mepolizumab	The risk or severity of adverse effects can be increased when Thiotepa is combined with Mepolizumab.
Abetimus	The risk or severity of adverse effects can be increased when Thiotepa is combined with Abetimus.
Belatacept	The risk or severity of adverse effects can be increased when Thiotepa is combined with Belatacept.
Bendamustine	The risk or severity of adverse effects can be increased when Thiotepa is combined with Bendamustine.

Target Protein

DNA

Referensi & Sumber

Synthesis reference: John Kazan, "Process for producing thiotepa." U.S. Patent US4918199, issued February, 1954.

Artikel (PubMed)

PMID: 10913381
Maanen MJ, Smeets CJ, Beijnen JH: Chemistry, pharmacology and pharmacokinetics of N,N',N" -triethylenethiophosphoramide (ThioTEPA). Cancer Treat Rev. 2000 Aug;26(4):257-68.

Contoh Produk & Brand

Produk: 37 • International brands: 1

Produk

Tepadina

Injection, powder, for solution • 15 mg • Intravenous • EU • Approved
Tepadina

Injection, powder, for solution • 15 mg/1 • Intracavitary; Intravenous; Intravesical • US • Approved
Tepadina

Injection, powder, for solution • 100 mg/1 • Intracavitary; Intravenous; Intravesical • US • Approved
Tepadina

Injection, powder, for solution • 100 mg • Intravenous • EU • Approved
Tepadina

Injection, powder, for solution • 400 mg • Intravenous • EU • Approved
Tepadina

Powder, for solution • 400 mg / bag • Intravenous • Canada • Approved
Tepadina

Powder, for solution • 15 mg / vial • Intravenous • Canada • Approved
Tepadina

Powder, for solution • 100 mg / vial • Intravenous • Canada • Approved

Menampilkan 8 dari 37 produk.

International Brands

Thioplex

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.

Deskripsi

Struktur Molekul 2D

Deskripsi metode visualisasi

1. Pendahuluan & Konsep

2. Sumber Data (Validasi)

3. Algoritma Visualisasi

4. Legenda Visual